GUJTHEMPharmaceuticals
Gujarat Themis Biosyn Ltd — Profit & Loss Statement
₹226.90
-6.10%
Gujarat Themis Biosyn Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | -0.01 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.25 | 0.25 | 0.26 | — |
| Normalized EBITDA | 71.55 Cr | 83.63 Cr | 80.14 Cr | 62.05 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | -0.05 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | -0.05 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Reconciled Depreciation | 5.65 Cr | 4.06 Cr | 2.58 Cr | 2.23 Cr | — |
| Reconciled Cost Of Revenue | 31.88 Cr | 41.61 Cr | 30.78 Cr | 20.89 Cr | — |
| EBITDA | 71.55 Cr | 83.63 Cr | 80.14 Cr | 62.00 Cr | — |
| EBIT | 65.90 Cr | 79.56 Cr | 77.56 Cr | 59.77 Cr | — |
| Net Interest Income | -0.36 Cr | -0.23 Cr | 4.95 Cr | 2.43 Cr | — |
| Interest Expense | 0.36 Cr | 0.23 Cr | 0.09 Cr | 0.73 Cr | — |
| Normalized Income | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.66 Cr | — |
| Net Income From Continuing And Discontinued Operation | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Total Expenses | 87.33 Cr | 94.62 Cr | 75.62 Cr | 57.62 Cr | — |
| Diluted Average Shares | 10.89 Cr | 10.90 Cr | 10.90 Cr | 10.90 Cr | — |
| Basic Average Shares | 10.89 Cr | 10.90 Cr | 10.90 Cr | 10.90 Cr | — |
| Diluted EPS | 4.48 | 5.43 | 5.32 | 4.00 | — |
| Basic EPS | 4.48 | 5.43 | 5.32 | 4.00 | — |
| Diluted NI Availto Com Stockholders | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Net Income Common Stockholders | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Net Income Including Noncontrolling Interests | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Net Income Continuous Operations | 48.77 Cr | 59.16 Cr | 57.97 Cr | 43.62 Cr | — |
| Tax Provision | 16.77 Cr | 20.17 Cr | 19.50 Cr | 15.41 Cr | — |
| Pretax Income | 65.54 Cr | 79.33 Cr | 77.46 Cr | 59.03 Cr | — |
| Other Non Operating Income Expenses | 2.43 Cr | 4.37 Cr | 14000.00 | 0.07 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | -0.05 Cr | — |
| Net Non Operating Interest Income Expense | -0.36 Cr | -0.23 Cr | 4.95 Cr | 2.43 Cr | — |
| Interest Expense Non Operating | 0.36 Cr | 0.23 Cr | 0.09 Cr | 0.73 Cr | — |
| Operating Income | 63.47 Cr | 75.20 Cr | 72.51 Cr | 56.57 Cr | — |
| Operating Expense | 55.45 Cr | 53.02 Cr | 44.84 Cr | 36.73 Cr | — |
| Other Operating Expenses | 37.44 Cr | 38.07 Cr | 29.70 Cr | 26.34 Cr | — |
| Depreciation And Amortization In Income Statement | 5.37 Cr | 3.54 Cr | 2.58 Cr | 2.23 Cr | — |
| Depreciation Income Statement | 5.37 Cr | 3.54 Cr | 2.58 Cr | 2.23 Cr | — |
| Gross Profit | 118.92 Cr | 128.21 Cr | 117.35 Cr | 93.30 Cr | — |
| Cost Of Revenue | 31.88 Cr | 41.61 Cr | 30.78 Cr | 20.89 Cr | — |
| Total Revenue | 150.80 Cr | 169.82 Cr | 148.13 Cr | 114.19 Cr | — |
| Operating Revenue | 150.80 Cr | 169.82 Cr | 148.13 Cr | 114.19 Cr | — |
| Interest Income | — | 4.04 Cr | 5.13 Cr | 3.26 Cr | 2.15 Cr |
| Rent Expense Supplemental | — | 0.18 Cr | 0.15 Cr | 0.08 Cr | 0.28 Cr |
| Total Other Finance Cost | — | 0.09 Cr | 0.08 Cr | 0.10 Cr | 0.19 Cr |
| Interest Income Non Operating | — | 4.04 Cr | 5.13 Cr | 3.26 Cr | 2.15 Cr |
| Research And Development | — | 3.89 Cr | 2.93 Cr | 0.45 Cr | 0.00 |
| Selling General And Administration | — | 1.76 Cr | 2.45 Cr | 1.12 Cr | 0.85 Cr |
| Selling And Marketing Expense | — | 0.36 Cr | 1.01 Cr | 0.29 Cr | 0.19 Cr |
| General And Administrative Expense | — | 1.39 Cr | 1.44 Cr | 0.83 Cr | 0.66 Cr |
| Rent And Landing Fees | — | 0.18 Cr | 0.15 Cr | 0.08 Cr | 0.28 Cr |
| Write Off | — | — | 0.00 | 0.05 Cr | 66000.00 |
| Other Special Charges | — | — | — | — | -0.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gujarat Themis Biosyn Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.